Avid Bioservices Inc (CDMO)

[sunstar]

Tradero, thanks. As SUNRISE finishes enrollment, Peregrine will certainly be leveraging their large network of clinics and hospitals to rapidly enroll new patients in the next round of trials, like the Bavituximab plus Durvalumab immunotherapy combination and HER2-negative metastatic breast cancer. Because the clinical centers are already fully engaged with Peregrine, these smaller open label trials should progress quickly and start providing new data for investigators.

The Bavi plus Durva lung cancer trial will exclude patients with:

“Prior therapy with a PD-1 or PD-L1 inhibitor, including durvalumab.” (which suggests how similar the PDs might be)

and,

“Prior therapy with bavituximab.”

https://clinicaltrials.gov/ct2/show/NCT02673814?term=bavituximab&rank=15

IMO

sunstar